analyzing-tumor-tissue-distribution-target-antigen-specific

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Monoclonal antibodies are high affinity multifunctional drugs that work by variable independent mechanisms to eliminate cancer cells. Over the last few ...

University of Virginia School of Medicine

Therapeutic antibodies targeting ovarian cancer (OvCa)-enriched receptors have largely been disappointing due to limited tumor-specific antibody-dependent cellular cytotoxicity. Here we report a symbiotic approach that is highly selective and superior compared with investigational clinical antibodies. This bispecific-anchored cytotoxicity activator antibody is rationally designed to instigate "cis" and "trans" cytotoxicity by combining specificities against folate receptor alpha-1 (FOLR1) and death receptor 5 (DR5). Whereas the in vivo agonist DR5 signaling requires FcγRIIB interaction, the FOLR1 anchor functions as a primary clustering point to retain and maintain a high level of tumor-specific apoptosis. The presented proof of concept study strategically makes use of a tumor cell-enriched anchor receptor for agonist death receptor targeting to potentially generate a clinically viable strategy for OvCa.

Gururaj Shivange

Laboratory of Novel Biologics,
Department of Biochemistry and Molecular Genetics,
UVA Cancer Center,
Department of Biochemistry and Molecular Genetics, UVA Cancer Center

University of Virginia School of Medicine

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Gururaj Shivange

Laboratory of Novel Biologics,Department of Biochemistry and Molecular Genetics,UVA Cancer Center,Department of Biochemistry and Molecular Genetics, UVA Cancer Center

University of Virginia School of Medicine

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Laboratory of Novel Biologics,
Department of Biochemistry and Molecular Genetics,
UVA Cancer Center,
Department of Biochemistry and Molecular Genetics, UVA Cancer Center